Management of cutaneous T cell lymphoma: new and emerging targets and treatment options

nagement of cutaneous T cell lymphoma: new and emerging targets and treatment options Review (5201) Total Article Views Authors: Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C Published Date March 2012 Volume 2012:4 Pages 75 - 89 DOI: http://dx.doi.org/10.2147/CMAR.S9660 Received: 15 November 2011 Accepted: 22 January 2012 Published: 12 March 2012 Janet Y Li1, Steven Horwitz2, Alison Moskowitz2, Patricia L Myskowski3, Melissa Pulitzer4, Christiane Querfeld3 1College of Physicians and Surgeons, Columbia University, 2Department of Medicine, Lymphoma Service, 3Department of Medicine, Dermatology Service, 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Over the last decade, new immunological and molecular pathways have been identified that not only influence CTCL phenotype and growth, but also provide targets for therapies and prognostication. This review will focus on recent advances in the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors (vorinostat and romidepsin), and pralatrexate in CTCL.